Thrivent Financial For Lutherans continued to hold its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 171,386 shares of the biotechnology company’s stock at the end of the second quarter. Thrivent Financial For Lutherans owned approximately 0.12% of Ironwood Pharmaceuticals worth $3,236,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in Ironwood Pharmaceuticals by 5.7% during the first quarter. Vanguard Group Inc. now owns 10,505,461 shares of the biotechnology company’s stock worth $179,223,000 after buying an additional 562,179 shares during the period. State Street Corp increased its position in Ironwood Pharmaceuticals by 5.1% during the first quarter. State Street Corp now owns 3,984,803 shares of the biotechnology company’s stock worth $67,979,000 after buying an additional 193,444 shares during the period. EcoR1 Capital LLC increased its position in Ironwood Pharmaceuticals by 1.8% during the first quarter. EcoR1 Capital LLC now owns 2,905,515 shares of the biotechnology company’s stock worth $49,568,000 after buying an additional 50,000 shares during the period. Pictet Asset Management Ltd. increased its position in Ironwood Pharmaceuticals by 16.9% during the second quarter. Pictet Asset Management Ltd. now owns 1,907,360 shares of the biotechnology company’s stock worth $33,779,000 after buying an additional 276,168 shares during the period. Finally, Point72 Asset Management L.P. increased its position in Ironwood Pharmaceuticals by 458.4% during the first quarter. Point72 Asset Management L.P. now owns 1,628,018 shares of the biotechnology company’s stock worth $27,774,000 after buying an additional 1,336,486 shares during the period. 97.90% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Thrivent Financial For Lutherans Continues to Hold Stake in Ironwood Pharmaceuticals, Inc. (IRWD)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/28/thrivent-financial-for-lutherans-continues-to-hold-stake-in-ironwood-pharmaceuticals-inc-irwd.html.

Several research analysts have commented on the company. BidaskClub raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Zacks Investment Research raised Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 17th. Mizuho lifted their price target on Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, July 4th. ValuEngine raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Wedbush reaffirmed a “neutral” rating and set a $13.00 price target on shares of Ironwood Pharmaceuticals in a research report on Friday, June 16th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $18.29.

Ironwood Pharmaceuticals, Inc. (IRWD) opened at 16.13 on Thursday. Ironwood Pharmaceuticals, Inc. has a 12-month low of $12.48 and a 12-month high of $19.94. The stock has a 50 day moving average price of $15.49 and a 200-day moving average price of $17.03. The firm’s market cap is $2.41 billion.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.05). The company had revenue of $65.10 million during the quarter, compared to the consensus estimate of $70.00 million. Ironwood Pharmaceuticals had a negative return on equity of 333.83% and a negative net margin of 52.97%. The company’s revenue for the quarter was up 19.7% on a year-over-year basis. During the same period last year, the business posted ($0.16) EPS. Equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post ($1.10) earnings per share for the current year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.